Trial Profile

A Phase 1, Open-label Study to Compare the Safety and Pharmacokinetics of Various Formulations of Orally Administered Superoxide Dismutase Mimetic GC4711 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 or GC4711 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avasopasem manganese (Primary) ; Rucosopasem manganese (Primary) ; Rucosopasem manganese (Primary)
Indications Cancer; Head and neck cancer; Stomatitis
Focus Adverse reactions; First in man
Sponsors Galera Therapeutics

01 Mar 2021 Status changed from recruiting to completed.
11 Sep 2019 Planned End Date changed from 1 Feb 2019 to 1 Dec 2020.
11 Sep 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com